Published in Gene Therapy Weekly, January 29th, 1996
Tests conducted by Dr. Brent Korba of Georgetown University, Washington, D.C., under a contract from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), in an HBV-producing human cell line demonstrated that a number of the company's EGS compounds were comparable or nearly comparable to the anti-HBV activity of the nucleoside analog 3TC.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.